A Randomized Controlled Clinical Trial on Efficacy and Safety of Anakinra in Patients With Severe Covid-19

A Randomized Controlled Clinical Trial on Efficacy and Safety of Anakinra in Patients With Severe Covid-19 Publisher Pubmed

Kharazmi AB¹ ; Moradi O² ; Haghighi M^{3, 4} ; Kouchek M⁵ ; Manafirasi A⁶ ; Raoufi M⁷ ; Shoaei D^{3, 4} ; Hadavand F^{3, 4} ; Nabavi M^{3, 4} ; Miri MM⁵ ; Salarian S⁵ ; Shojaei S⁵ ; Khalili S¹ ; Sistanizad M^{2, 8} Show All Authors

Kharazmi AB¹
Moradi O²
Haghighi M^{3, 4}
Kouchek M⁵
Manafirasi A⁶
Raoufi M⁷
Shoaei D^{3, 4}
Hadavand F^{3, 4}
Nabavi M^{3, 4}
Miri MM⁵
Salarian S⁵
Shojaei S⁵
Khalili S¹
Sistanizad M^{2, 8}
Sadeghi S⁹
Karagah A²
Asgari S¹⁰
Jaffaraghaei M¹¹
Araghi S¹²

Source: Immunity# Inflammation and Disease Published:2022

Abstract

Introduction: Hyperinflammatory state has a role in the pathogenesis of COVID-19. Anakinra could reduce inflammation and help to combat the condition. In this study, we aimed to assess the safety and efficacy of anakinra (PerkinRA®) in severe COVID-19. Method: The study was an open-label, randomized, controlled trial conducted in Imam Hossein Medical Center from May to July 2020. Patients with a confirmed diagnosis of COVID-19 were included in this study. We administered anakinra 100 mg daily intravenously. All patients received COVID-19 pharmacotherapy based on the represented national guideline. The need for invasive mechanical ventilation is considered the primary outcome. Results: Thirty patients were included in this study, and 15 of them received Anakinra. Nineteen patients were male (63.3%), and 11 were female (36.7%). The mean age of patients was 55.77 ± 15.89 years. In the intervention group, the need for invasive mechanical ventilation was significantly reduced compared to the control group (20.0% vs. 66.7%, p =.010). Also, these patients had a significantly lower length of hospital stay (p =.043). No significant higher rate of infection was recorded. Conclusion: Anakinra as an immunomodulatory agent has been associated with the reduced need for mechanical ventilation in patients admitted to intensive care units because of severe COVID-19. The medication reduced the hospital length of stay. Furthermore, no increased risk of infection was observed. Further randomized placebo-controlled trials with a larger sample size are needed to confirm these findings. © 2021 The Authors. Immunity, Inflammation and Disease published by John Wiley & Sons Ltd.

Related Docs

View other Related Docs

1. Current Evidence on the Use of Anakinra in Covid-19, International Immunopharmacology (2022)

2. Immunomodulatory-Based Therapy As a Potential Promising Treatment Strategy Against Severe Covid-19 Patients: A Systematic Review, International Immunopharmacology (2020)

3. Cancer and Coronavirus Disease (Covid-19): Comorbidity, Mechanical Ventilation, and Death Risk, Journal of Gastrointestinal Cancer (2021)

Experts (# of related papers)

View all Related Experts

Mohammadreza Salehi (3)

Reza Malekzadeh (2)

Style	Citing Format
MLA	Kharazmi AB, et al.. "A Randomized Controlled Clinical Trial on Efficacy and Safety of Anakinra in Patients With Severe Covid-19." Immunity# Inflammation and Disease, vol. 10, no. 2, 2022, pp. 201-208.
APA	Kharazmi AB, Moradi O, Haghighi M, Kouchek M, Manafirasi A, Raoufi M, Shoaei D, Hadavand F, Nabavi M, Miri MM, Salarian S, Shojaei S, Khalili S, Sistanizad M, Sadeghi S, Karagah A, Asgari S, Jaffaraghaei M, Araghi S (2022). A Randomized Controlled Clinical Trial on Efficacy and Safety of Anakinra in Patients With Severe Covid-19. Immunity# Inflammation and Disease, 10(2), 201-208.
Chicago	Kharazmi AB, Moradi O, Haghighi M, Kouchek M, Manafirasi A, Raoufi M, Shoaei D, et al.. "A Randomized Controlled Clinical Trial on Efficacy and Safety of Anakinra in Patients With Severe Covid-19." Immunity# Inflammation and Disease 10, no. 2 (2022): 201-208.
Harvard	Kharazmi AB et al. (2022) 'A Randomized Controlled Clinical Trial on Efficacy and Safety of Anakinra in Patients With Severe Covid-19', Immunity# Inflammation and Disease, 10(2), pp. 201-208.
Vancouver	Kharazmi AB, Moradi O, Haghighi M, Kouchek M, Manafirasi A, Raoufi M, et al.. A Randomized Controlled Clinical Trial on Efficacy and Safety of Anakinra in Patients With Severe Covid-19. Immunity# Inflammation and Disease. 2022;10(2):201-208.
BibTex	@article{ author = {Kharazmi AB and Moradi O and Haghighi M and Kouchek M and Manafirasi A and Raoufi M and Shoaei D and Hadavand F and Nabavi M and Miri MM and Salarian S and Shojaei S and Khalili S and Sistanizad M and Sadeghi S and Karagah A and Asgari S and Jaffaraghaei M and Araghi S}, title = {A Randomized Controlled Clinical Trial on Efficacy and Safety of Anakinra in Patients With Severe Covid-19}, journal = {Immunity# Inflammation and Disease}, volume = {10}, number = {2}, pages = {201-208}, year = {2022} }
RIS	TY - JOUR AU - Kharazmi AB AU - Moradi O AU - Haghighi M AU - Kouchek M AU - Manafirasi A AU - Raoufi M AU - Shoaei D AU - Hadavand F AU - Nabavi M AU - Miri MM AU - Salarian S AU - Shojaei S AU - Khalili S AU - Sistanizad M AU - Sadeghi S AU - Karagah A AU - Asgari S AU - Jaffaraghaei M AU - Araghi S TI - A Randomized Controlled Clinical Trial on Efficacy and Safety of Anakinra in Patients With Severe Covid-19 JO - Immunity# Inflammation and Disease VL - 10 IS - 2 SP - 201 EP - 208 PY - 2022 ER -

Science Communicator Platform

Authors

Abstract